Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Operating Leases (2019 - 2026)

Corvus Pharmaceuticals' Operating Leases history spans 8 years, with the latest figure at $406000.0 for Q1 2026.

  • Quarterly Operating Leases fell 51.32% to $406000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $406000.0 through Mar 2026, down 51.32% year-over-year, with the annual reading at $534000.0 for FY2025, 43.01% down from the prior year.
  • Operating Leases came in at $406000.0 for Q1 2026, down from $534000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $2.3 million in Q1 2022 to a low of $354000.0 in Q3 2023.
  • The 5-year median for Operating Leases is $834000.0 (2025), against an average of $999823.5.
  • Year-over-year, Operating Leases surged 216.8% in 2022 and then crashed 79.04% in 2023.
  • Corvus Pharmaceuticals' Operating Leases stood at $1.4 million in 2022, then increased by 0.07% to $1.4 million in 2023, then crashed by 31.8% to $937000.0 in 2024, then crashed by 43.01% to $534000.0 in 2025, then dropped by 23.97% to $406000.0 in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Operating Leases are $406000.0 (Q1 2026), $534000.0 (Q4 2025), and $632000.0 (Q3 2025).